Revenue and Growth Expectations: West Pharmaceutical Services reported Q4 2024 revenues of $748.8 million, indicating a 3.3% organic growth. While proprietary product organic revenues saw a decline of 4.5%, there are expectations for proprietary products to achieve organic revenue growth in the range of 2% to 3% in FY 2025, with a stronger emphasis on HPP components growth projected at mid to high single digits.

Challenges in Contract Manufacturing: A notable challenge is the decision to exit contracts with continuous glucose monitoring (CGM) customers due to unappealing financial metrics. This exit is anticipated to create a revenue "air pocket" in 2025, impacting earnings until new opportunities replace it. This segment is expected to decline by 200 basis points in margins in FY 2025.

Investment in High-Value Products (HVP): West continues to focus on increasing capacity in the high-value products segment, particularly relating to GLP-1 injectables and biologics. Strategic investments made in HVP capacity are expected to drive incremental growth, with a strong win rate for HPP components in the biologics market.